噻托溴铵治疗慢性阻塞性肺疾病稳定期的临床疗效研究

目的探讨噻托溴铵治疗慢性阻塞性肺疾病(COPD)稳定期的临床疗效。方法选取2012年在南昌大学第一附属医院进行治疗的COPD稳定期患者200例,随机分为治疗组和对照组,各100例。对照组患者给予COPD常规治疗,治疗组患者在COPD常规治疗基础上给予噻托溴铵治疗,均连续治疗8周后随访6个月。比较两组患者治疗前后肺功能指标,包括:第一秒用力呼气末容积(FEV1)、用力肺活量(FVC)及FEV1/FVC比值;观察两组患者治疗前和随访3、6个月时呼吸困难指数(m MRC)和6分钟步行距离(6MWT)及治疗期间不良反应发生情况。结果两组患者治疗前FEV1、FVC及FEV1/FVC比值比较,差异无统计学意义(P0.05);治疗组患者治疗后FEV1、FVC及FEV1/FVC比值均高于对照组(P0.05)。两组患者治疗前m MRC和6MWT比较,差异无统计学意义(P0.05);治疗组患者随访3个月、6个月时m MRC低于对照组,6MWT长于对照组(P0.05)。治疗组患者不良反应发生率为7%,与对照组的8%比较,差异无统计学意义(P0.05)。结论噻托溴铵能改善COPD稳定期患者肺功能,缓解临床症状,提升运动耐量,且安全性良好。

Effect of Tiotropium Bromide on Stable Patients with Chronic Obstructive Pulmonary Disease

Objective To investigate the clinical effect of tiotropium bromide on stable patients with chronic obstruc- tive pulmonary disease. Methods A total of 200 stable patients with chronic obstructive pulmonary disease admitted to the First Affiliated Hospital of Nanchang University were selected in 2012,and they were randomly divided into treatment group and con- trol group,100 cases in each. Both groups given conventional treatment,while treatment group given extra tiotropium bro- mide. Both groups treated for 8 weeks and then followed up for 6 months. Lung function index including FEV1、FVC and FEV1 /FVC ratio before and after treatment between the two groups were compared;mMRC and 6MWT before treatment and 3,6 -month after fellow - up,and incidence of adverse reactions were observed. Results There was no significant differences of FEV1、FVC and FEV1 / FVC between the two groups before treatment（ P 〉 0. 05）,but above index of treatment group were higher than those of control group（P 〈 0. 05）. There was no significant differences of mMRC and 6MWT between the two groups before treatment（P 〉 0. 05）,but mMRC of treatment group was higher,6MWT was longer than that of control group 3,6 -month after fellow - up,respectively（P 〈 0. 05）. The incidence of adverse reactions of treatment group was 7% ,that of con- trol group was 8% ,the difference was not significantly different（P 〉 0. 05）. Conclusion Tiotropium bromide can significantly improve the lung function and exercise capacity of stable patients with chronic obstructive pulmonary disease,relieve the clinical symptoms,and is safe.